Rapport Therapeutics, Inc. RAPP Additional Paid-In Capital
Additional Paid-In Capital at other companies
Other financials
Where this comes from
Reported directly by Rapport Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AdditionalPaidInCapitalCommonStock.
The official record: Rapport Therapeutics, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Rapport Therapeutics, Inc.'s additional paid-in capital.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Rapport Therapeutics, Inc.'s additional paid-in capital?
- Rapport Therapeutics, Inc. (RAPP) reported additional paid-in capital of $727.05M in Q1 2026.
- How has Rapport Therapeutics, Inc.'s additional paid-in capital changed year-over-year?
- Rapport Therapeutics, Inc.'s additional paid-in capital increased by 67.6% year-over-year, from $433.7M to $727.05M.
- What is the long-term trend for Rapport Therapeutics, Inc.'s additional paid-in capital?
- Over 2 years (2023 to 2025), Rapport Therapeutics, Inc.'s additional paid-in capital has grown at a 502.8% compound annual growth rate (CAGR), from $19.8M to $719.29M.
- What does additional paid-in capital mean?
- This represents the excess amount paid by investors for common shares over their par value. It is a key component of shareholders' equity that captures the capital raised through equity offerings beyond the nominal value of the stock. It reflects the historical market premium at which the company has issued its shares.